Jim Birchenough
Stock Analyst at Wells Fargo
(2.58)
# 2,113
Out of 4,784 analysts
41
Total ratings
42.86%
Success rate
19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.82 | +143.90% | 2 | Dec 31, 2024 | |
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $1.73 | +73.41% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $36.99 | +89.24% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.35 | +1,602.13% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $12.37 | +288.04% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.21 | +3,298.06% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $0.85 | +15,206.72% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.59 | +780.50% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $31.12 | +365.94% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $111.79 | -43.64% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $31.60 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $12.47 | +349.08% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $637.36 | +15.16% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $4.92 | +3,558.54% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $5.08 | +549.61% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.82
Upside: +143.90%
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $1.73
Upside: +73.41%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $36.99
Upside: +89.24%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.35
Upside: +1,602.13%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $12.37
Upside: +288.04%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.21
Upside: +3,298.06%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $0.85
Upside: +15,206.72%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.59
Upside: +780.50%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $31.12
Upside: +365.94%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $111.79
Upside: -43.64%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $31.60
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $12.47
Upside: +349.08%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $637.36
Upside: +15.16%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $4.92
Upside: +3,558.54%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $5.08
Upside: +549.61%